SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glaxosmithkline Pharmaceuticals board to consider unaudited financial results

17 Jul 2024 Evaluate
Glaxosmithkline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on Friday, 2nd August 2024, to consider and approval of Un-audited financial results for the quarter ended 30th June 2024.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2419.10 12.85 (0.53%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×